Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 162

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

Open access
Landmesser, Ulf, John Chapman, M., Farnier, Michel, Gencer, Baris, Gielen, Stephan, Hovingh, G. Kees, Lüscher, Thomas F., Sinning, David, Tokgözoğlu, Lale, Wiklund, Olov, Zamorano, Jose Luis, Pinto, Fausto J., Catapano, Alberico L., on behalf of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) · 2016 · European Heart Journal

Abstract

Atherosclerotic cardiovascular disease (ASCVD) underlies the thrombotic events intimately associated with myocardial infarction, a significant proportion of ischaemic strokes, as well as critical limb ischaemia. Such events confer substantial mortality, physical and/or mental disability, and cost for the individual and society.1 Indeed, no finite value can be attributed to the cost to the individual, although survival and subsequent quality of life are critical factors, especially in young individuals with ASCVD.2 Although the advent of precision medicine and innovative treatments have been the driver for an individualized approach to patient management and prevention, the ever-increasing financial restraints in healthcare systems worldwide often require clinical benefit to be balanced with the cost of a given intervention. The causality of plasma low-density lipoprotein-cholesterol (LDL-C) and reduced LDL receptor-mediated LDL uptake in the pathophysiology of ASCVD has been established beyond any reasonable doubt.3 For patients at very high risk of premature ASCVD, including those with familial hypercholesterolaemia (FH) without ASCVD, elevated LDL-C is a common risk factor.4,5 Indeed, high LDL-C levels are prevalent in both FH and non-FH patients in the acute secondary prevention setting.6 In the case of the latter, polygenic effects may account for an elevated LDL-C concentration as reflected by genetic risk scores.7 The key clinical issue is attainment of guideline-recommended LDL-C levels (<1.8 mmol/L or 70 mg/dL) for patients at very high cardiovascular risk.4 Even with high-intensity statin treatment, a substantial proportion of these patients will remain above this LDL-C goal due to <50% lowering of LDL-C levels, in part as result of pharmacogenetic effects that underlie wide inter-individual variability in statin response.8 This eventuality emphasizes the need for additional LDL-C reduction with new therapeutic approaches which target these atherogenic particles. Proprotein convertase subtilisin/kexin type 9 (PCSK9), a member of the serine protease family, plays a key role in the regulation of hepatic LDL receptor activity.9 Subjects with sequence variants in the gene coding for PCSK9 (loss-of-function) that are associated with lower levels of LDL-C have a substantially reduced risk of coronary disease;10 conversely, subjects heterozygous for a gain-of-function mutation of PCSK9 present with a phenotype consistent with FH.11 These findings have set the stage to investigate PCSK9 inhibition as an innovative therapeutic approach to improve control of elevated LDL-C levels. Several clinical studies with different monoclonal antibodies against circulating PCSK9, either alone or in addition to statin therapy, have confirmed profound reductions of LDL-C levels (by up to ∼60%).12–15 Evidence to date indicates that these PCSK9 inhibitors are generally well tolerated, with injection site reactions typically reported by about 5% of patients in clinical trials,14,15 and no increase in the frequency of creatine kinase (CK) elevations, myalgia or muscle symptoms.13 A recent meta-analysis has suggested a possible signal for increased frequency of neurocognitive events,12 although it should be borne in mind that reporting of neurocognitive symptoms was not systematically defined in these trials, and the absolute numbers of events were low. Although larger and longer-term studies are needed to further establish safety and efficacy for reduction of cardiovascular events in patients at high and very high cardiovascular risk, one posthoc analysis with alirocumab and one prespecified exploratory analysis with evolocumab have reported a reduced rate of major adverse cardiovascular events associated with PCSK9 inhibition.14,15 These data have to be interpreted with caution, because the number of cardiovascular events in each study was low; definitive large randomized trials on the efficacy and safety of this novel therapeutic approach to reduce cardiovascular events are ongoing.16,17 Moreover, further data on the safety of PCSK9 antibody therapy with respect to neurocognitive effects are awaited from the EBBINGHAUS study with evolocumab, as well as planned studies with alirocumab and bococizumab.18 As two antibodies are already approved in Europe (see Box 1) and in clinical use, the main purpose of this consensus document is to discuss the appropriate clinical use of PCSK9 antibodies in patients at very high cardiovascular risk who have substantially elevated LDL-C levels on maximal statin/ezetimibe therapy. The LDL-C threshold values for considering PCSK9 monoclonal antibody therapy were agreed based on consideration of absolute cardiovascular risk and the absolute LDL-C reduction required. This approach is supported by the Cholesterol Treatment Trialists’ Collaboration, which showed that absolute LDL-C reduction is one of the key determinants of absolute cardiovascular risk reduction.19 Approved indications for aliroc

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehw480

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 162

Metadata

Authors
Landmesser, U., John Chapman, M., Farnier, M., Gencer, B., Gielen, S., Hovingh, G. K., Lüscher, T. F., Sinning, D., Tokgözoğlu, L., Wiklund, O., Zamorano, J. L., Pinto, F. J., Catapano, A. L., & on behalf of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
Venue
European Heart Journal
Published
2016-10-27
Volume
38
Issue
29
Pages
ehw480
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2546044729
Cited by
162
References
26
FWCI
39.50
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. https://app.cochat.ai/papers/10.1093/eurheartj/ehw480
The paper
Landmesser, U., John Chapman, M., Farnier, M., Gencer, B., Gielen, S., Hovingh, G. K., Lüscher, T. F., Sinning, D., Tokgözoğlu, L., Wiklund, O., Zamorano, J. L., Pinto, F. J., Catapano, A. L., & on behalf of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2016). European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. European Heart Journal. https://doi.org/10.1093/eurheartj/ehw480

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.